Arcturus Therapeutics to Attend Upcoming Investor Conferences
August 17 2023 - 8:30AM
Business Wire
Arcturus Therapeutics Holdings Inc. (the “Company”, “Arcturus”,
Nasdaq: ARCT), a global late-stage clinical messenger RNA medicines
company focused on the development of infectious disease vaccines
and opportunities within liver and respiratory rare diseases, today
announced that the Company will participate in the following
investor conferences:
Citi’s 18th Annual BioPharma Conference 2023 (Hosting 1x1
meetings)
- Wednesday, September 6 – 7, 2023
2023 Wells Fargo Health Conference (Fireside Chat)
- Thursday, September 7, 2023 (1:30 p.m. ET)
H.C. Wainwright 25th Annual Global Investment Conference 2023
(Presentation)
- Monday, September 11, 2023 (8:30 a.m. ET)
Baird Global Healthcare Conference 2023
(Presentation)
- Tuesday, September 12, 2023 (3:10 p.m. ET)
2023 Cantor Fitzgerald Global Healthcare Conference (Fireside
Chat)
- Tuesday - Thursday, September 26 – 28, 2023
Chardan’s 7th Annual Genetic Medicines Conference 2023
(Hosting 1X1 meetings)
- Monday - Tuesday, October 2 – 3, 2023
Webcast links can be found under Investor Relations/Events
section of Arcturus’ website.
About Arcturus Therapeutics
Founded in 2013 and based in San Diego, California, Arcturus
Therapeutics Holdings Inc. (Nasdaq: ARCT) is a global late-stage
clinical mRNA medicines and vaccines company with enabling
technologies: (i) LUNAR® lipid-mediated delivery, (ii) STARR® mRNA
Technology (samRNA) and (iii) mRNA drug substance along with drug
product manufacturing expertise. The Company has ongoing
collaborations with CSL Seqirus and Meiji Seika Pharma, and a joint
venture with ARCALIS. Arcturus’ pipeline includes RNA therapeutic
candidates to potentially treat ornithine transcarbamylase
deficiency and cystic fibrosis, along with its partnered mRNA
vaccine programs for SARS-CoV-2 (COVID-19) and influenza. Arcturus’
versatile RNA therapeutics platforms can be applied toward multiple
types of nucleic acid medicines including messenger RNA, small
interfering RNA, circular RNA, antisense RNA, self-amplifying RNA,
DNA, and gene editing therapeutics. Arcturus’ technologies are
covered by its extensive patent portfolio (patents and patent
applications issued in the U.S., Europe, Japan, China, and other
countries). For more information, visit www.ArcturusRx.com. In
addition, please connect with us on Twitter and LinkedIn.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230817580897/en/
IR and Media Contacts Arcturus Therapeutics Neda
Safarzadeh VP, Head of IR/PR/Marketing (858) 900-2682
IR@ArcturusRx.com
Kendall Investor Relations Carlo Tanzi, Ph.D. (617) 914-0008
ctanzi@kendallir.com
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcturus Therapeutics (NASDAQ:ARCT)
Historical Stock Chart
From May 2023 to May 2024